Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Silexion Therapeutics ( (SLXN) ) has shared an update.
On September 15, 2025, Silexion Therapeutics Corp issued 450,000 ordinary shares to Moringa Sponsor, LP, converting $1.8 million of its outstanding promissory note. This move is part of a series of transactions aimed at increasing the company’s shareholders’ equity, which now stands at approximately $9.41 million, ensuring compliance with Nasdaq’s equity requirements. The company has been actively working to maintain its Nasdaq listing, having received a favorable decision from a Nasdaq hearings panel in July 2025, which allowed it to remain listed subject to certain conditions. These financial maneuvers, including a public offering and warrant exercises, have significantly improved Silexion’s financial standing and are expected to secure its long-term compliance with Nasdaq’s listing rules.
The most recent analyst rating on (SLXN) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.
Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Silexion Therapeutics Corp is a Cayman Islands-based company operating in the biotechnology industry. The company focuses on developing therapeutic solutions and has engaged in financial restructuring to enhance its market positioning.
Average Trading Volume: 382,683
Technical Sentiment Signal: Sell
Current Market Cap: $2.98M
For detailed information about SLXN stock, go to TipRanks’ Stock Analysis page.